DexCom

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade DexCom 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About DXCM

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. 

CEO
Jacob S. Leach
CEOJacob S. Leach
Employees
11,100
Employees11,100
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1999
Founded1999
Employees
11,100
Employees11,100

DXCM Key Statistics

Market cap
27.55B
Market cap27.55B
Price-Earnings ratio
33.35
Price-Earnings ratio33.35
Dividend yield
Dividend yield
Average volume
4.16M
Average volume4.16M
High today
$71.85
High today$71.85
Low today
$69.79
Low today$69.79
Open price
$71.16
Open price$71.16
Volume
1.03M
Volume1.03M
52 Week high
$89.98
52 Week high$89.98
52 Week low
$54.11
52 Week low$54.11

Stock Snapshot

With a market cap of 27.55B, DexCom(DXCM) trades at $71.40. The stock has a price-to-earnings ratio of 33.35.

On 2026-07-24, DexCom(DXCM) stock traded between a low of $69.79 and a high of $71.85. Shares are currently priced at $71.40, which is +2.3% above the low and -0.6% below the high.

DexCom(DXCM) shares are trading with a volume of 1.03M, against a daily average of 4.16M.

During the past year, DexCom(DXCM) stock moved between $54.11 at its lowest and $89.98 at its peak.

During the past year, DexCom(DXCM) stock moved between $54.11 at its lowest and $89.98 at its peak.

DXCM News

TipRanks 2d
DexCom selected by FDA as first participant in TEMPO pilot

The U.S. Food and Drug Administration announced the first manufacturer selected for the Technology-Enabled Meaningful Patient Outcomes, or TEMPO, for Digital He...

Simply Wall St 6d
DexCom Back In Focus As Canada Approval Tests Its Valuation

DexCom (DXCM) stock is back in focus after Health Canada authorized the Dexcom G7 15 Day continuous glucose monitoring system, a longer wear CGM that could broa...

DexCom Back In Focus As Canada Approval Tests Its Valuation

Analyst ratings

83%

of 30 ratings
Buy
83.3%
Hold
16.7%
Sell
0%

People also own

Based on the portfolios of people who own DXCM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.